Atypical presentation of acute macular neuroretinopathy

Article

A case report

The clinical examination

BCVA: 10/10 (0.0 LogMar) with sf –1.00 = cyl –3.50 (90)

Ocular pressure: 11 mmHg

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
Related Content
Exonate announces CLEAR-DE trial for EXN407

Exonate announces CLEAR-DE trial for EXN407

Kassi Filkins
July 30th 2025
Article

Exonate initiates a phase 2b trial for EXN407, a groundbreaking eye drop treatment for diabetic retinopathy

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

The retina undergoing fundus imaging. Concept image for retinal imgaging, OCT, CA, cardiac angiography, optical coherence tomography and biomarkers. Image credit: ©Panama – stock.adobe.com

Biomarkers of microvascular retinal perfusion indicating coronary heart disease

Lynda Charters
July 29th 2025
Article

Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A brain and a fungus mushroom both depicted in illustration. Concept image for fungal infection and diabetic eye disease. Image credit: ©Anson – stock.adobe.com – generated with AI

Fungal infection and vision impact in patients with diabetic eye disease

Lynda Charters
July 25th 2025
Article

Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes

Three ways we’re building confidence through evidence in myopia management

Three ways we’re building confidence through evidence in myopia management

July 25th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.